ERBB2 and breast carcinoma: In conclusion, continuation of planned Trastuzumab therapy among patients with low risk for development of severe cardiac events may be a safe and effective approach in patients with high-risk breast cancer where the continuation of anti-HER2 therapy carries substantial improvement in survival.